Pfizer Inc
Latest Pfizer Inc News and Updates
Xalkori Label Expansion May Boost Pfizer’s Sales in 2016
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
Viagra May Witness a Decline in Revenues in 2016
Wall Street analysts estimate that Viagra’s sales in 2016 will reach approximately $1.6 billion, which would be a year-over-year (or YoY) decline of about 7.7%.
Pfizer Has a Revenue-Boosting Treatment to Help Smokers Quit
Approved by the FDA on May 11, 2006, Chantix, also known as Champix, is used as an aid to help cigarette smokers quit the habit of smoking.
How GILD Plans to Battle through Impending HIV Patent Cliff
Gilead Sciences (GILD) is the leading biotechnology player in the global HIV market.
Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]
Teva Pharmaceutical Still Dominates the Generic Market in Europe
With a share of about 14%, Teva Pharmaceutical Industries (TEVA) is currently the top-ranking player in the European generic pharmaceutical market.
Teva Is Well Positioned for New Trends in the US Generic Market
Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market.
Winning? We Review How Teva Dominates Generic Drug Space
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
GlaxoSmithKline Giving a Shot to Its Vaccines Business
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.
Pfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion.
Market Cheers FDA’s Fast Tracking of BIIB’s Alzheimer’s Treatment
The U.S. Food and Drug Administration (or FDA) recently awarded the fast track status to aducanumab following the positive results of Biogen’s pre-clinical research.
Pfizer’s Essential Health Business: What You Need to Know
In this series, we’ll discuss in detail how Pfizer plans to revive growth for the falling Essential Health business.
Why Is Sanofi Expanding in the CHC Space?
Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.
Understanding Sanofi’s Strategic Priority
As of June 30, 2016, the animal health business was Sanofi’s operating segment. It will remain an operating segment until the transaction closes.
Analyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim
Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.
A Look at Pfizer’s Innovative Health Business
In the second quarter of 2016, Pfizer (PFE) reorganized its Innovative Pharmaceutical and Consumer Healthcare operations as the Innovative Health business segment.
Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?
BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.
Why Pfizer’s Enbrel Faces a Sales Decline
Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively.
Teva’s Asthma Segment: What Could Boost Its Revenues in 2016?
On March 23, 2016, the FDA approved Cinqair (reslizumab) as a maintenance therapy for patients with severe asthma.
How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?
GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
What Is Allergan’s Inorganic Growth Strategy?
Actavis acquired Allergan in March 2015, and the company changed its name from Actavis to Allergan (AGN).
The Evolution of Hemophilia Treatment—And What It Means for BioMarin
BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.
Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors.
What’s Novartis’s New Structure?
Novartis (NVS) has restructured its entire business into two parts: continuing operations and discontinuing operations.
What Are Novartis’s Key Business Segments?
Novartis’s new structure includes only three business segments: pharmaceuticals, Alcon, and Sandoz.
What’s Allergan’s Growth Strategy?
Allergan’s new industry model, “growth pharma,” is based on identifying five characteristics that boost company growth and differentiate it from its peers.
Inside Gilead Sciences’ Involvement in TAF Therapies
On March 01, 2016, the FDA approved Gilead Sciences’ TAF-based HIV drug, Odefsey, for the treatment of certain HIV-1 afflicted patients.
How Did Edwards Lifesciences’ Critical Care Segment Fare in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$134 million was contributed by the company’s Critical Care segment.
A Look at Baxalta’s Product Segments
Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.
Can Xyrem Maintain Leadership in the Narcolepsy Space?
Jazz Pharmaceuticals’ (JAZZ) Xyrem is a drug for cataplexy and excessive daytime sleepiness occurring in patients with narcolepsy, a serious orphan disease.
What Is a Bridging Study?
A bridging study on a drug is an additional study performed in a new region to provide clinical data on safety, efficacy, dosage, and dose regimen.
How Is the Global Pharmaceutical Industry Doing?
Some of the challenges the pharmaceutical industry faces include R&D failures, changes in regulatory procedures, litigation, patent expiries, and foreign currency movements.
Why Did Amgen Implement Multi-Pronged Strategy for Repatha?
Amgen (AMGN) is expecting to strengthen Repatha’s brand position in the global cardiovascular market in 2016 through a multi-pronged strategy.
Decoding Roche’s Performance on EV-to-EBITDA Basis
As of March 8, Roche Holding was trading at a forward EV-to-EBITDA multiple of 9.73x—a discount compared to Bristol-Myers Squibb’s 16.09x.
Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15
Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.
Can Consumer Healthcare Drive Sanofi’s Revenue?
The CHC (consumer healthcare) market forms a part of Sanofi’s (SNY) pharmaceutical segment.
Mylan Product Portfolio across Key Therapeutic Areas
Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.
CheckMate -066 Study Supports Opdivo’s Approval
The FDA has now approved Opdivo for the treatment of BRAF WT (wild-type) melanoma, based on the results of a phase 3 study called CheckMate -066.
Pfizer-Allergan Deal: Pfizer Will Combine with Allergan
On November 23, two of the big pharmaceutical companies—Pfizer and Allergan—announced the biggest merger transaction ever in pharmaceuticals.
JAVELIN Series: Clinical Studies of Avelumab
The JAVELIN series is a clinical trial program for the use of Avelumab for treatment of multiple types of cancer, including Merkel cell carcinoma.
Existing Drugs for Renal Cell Carcinoma
The FDA has accepted Bristol-Myers Squibb’s (BMY) supplemental biologics license application, or sBLA, for Opdivo for the treatment of patients with advanced renal cell carcinoma.
Allergan Drives the Performance of XLV’s Top Ten Holdings
Allergan gained 14.9% for the week ended October 30, 2015. The company’s stocks gained on the news of a possible merger with Pfizer.
Alkermes’s Aristada and Its FDA Approval for Schizophrenia
Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.
Perrigo Leads the Over-the-Counter Store-Branded Products Market
Perrigo is a market leader in over-the-counter store-branded products. Its leadership position extends to major geographies such as the US, the UK, and Mexico.
Novo Nordisk: Core Capabilities Differentiate It from Competition
Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.
Novo Nordisk Plans to Pursue Leadership in Hemophilia Market
Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.
AbbVie’s Endocrinology, Cardiovascular, and Rare Disease Segments
AbbVie has a diversified offering of drugs for the treatment of conditions related to endocrinology, cardiovascular, and rare disease.
AbbVie Has a Strong Metabolic and Hormonal Portfolio
AbbVie’s metabolic and hormonal portfolio offers drugs such as AndroGel, Creon, and Synthroid to address various medical conditions.
Humira Continues to Dominate AbbVie’s Revenues
Since Humira’s launch in the US market in 2002, Abbott Laboratories and its spin-off AbbVie have aggressively expanded the drug’s approved indications.
An Overview of Regeneron’s Business Model
Regeneron generates revenues in three ways: product sales, revenues earned through collaboration arrangements, and revenues earned from licensing proprietary technology.
